Blog | Insights on drug delivery & innovation

Moving faster, with confidence: An interview with Ulrike Bauer, Chief Business Officer at Ypsomed

How can pharma and biotech companies accelerate drug-device programs without shifting risk or bottlenecks further downstream? In this interview, Ypsomed Chief Business Officer Ulrike Bauer discusses how platform flexibility, device readiness and …

For the record: How past experience enables future success

Jakob Lange and Shawn James discuss the value of the experience hidden behind metrics such as completed projects and commercialized devices – the wealth of accumulated process knowledge that enables a company to bring hard-learned lessons forwards.

Flying on two wings: How Ypsomed built a dual-engine strategy to lead China's drug delivery market

How can pharmaceutical companies succeed in China's evolving drug delivery market? Cui Hong, Orfeo Niedermann and Shawn James explore how Ypsomed's dual-engine strategy is making the difference.

Post-conference summary: Combination Products Summit 2026

The 8th Annual Combination Products Summit, organized by PharmaEd on May 27–28, 2026, brought together stakeholders from across the combination product ecosystem — pharmaceutical companies, device manufacturers, regulatory consultancies, and …

MIDBA: A new regulatory approach to clinical device bridging

The development of drug-device combination products continues to evolve, with increasing attention on how clinical bridging between different delivery systems is handled. In this context, regulatory approaches that support more efficient and …

Biobased plastics in drug delivery: From material equivalence to systemic decarbonization

Biobased plastics can cut carbon without changing performance or regulatory status. In our latest blog, Nadine Kaufmann and Michael Schori explore how material equivalence, lifecycle thinking, and scale enable real decarbonization in drug delivery …

The compass for innovation: Regulatory Affairs at Ypsomed

Acting as the compass for innovation, Ypsomed’s regulatory strategy steers ideas through development to deliver safe, compliant solutions to patients worldwide.

SmartPilot - the first and only FDA-cleared connectivity solution for autoinjectors

SmartPilot is a digital add-on that transforms the YpsoMate autoinjector into a connected device. It automatically captures injection data, transmits it into the digital ecosystem, and transforms it into insights for patients, healthcare …

Automated assembly for fast-track design verification of YpsoMate platforms

Discover how Ypsomed’s innovative in-house assembly system streamlines workflows, enhances precision and slashes verification times, helping customers bring their products to market with speed and confidence.

Welcome to the Ypsomed Blog